Table 3.
GVHD characteristics of the efficacy and safety populations
| Characteristics | Primary efficacy population (n = 49) | Safety analysis population (n = 71) |
|---|---|---|
| Prior GVHD treatment | ||
| Failed steroids alone | 49 (100%) | 49 (69%) |
| Failed steroids + other(s) | 0 | 12 (17%) |
| Undertreated | 0 | 10 (14%) |
| Baseline GVHD grade | ||
| Grade 2 | 13 (27%) | 22 (31%) |
| Grade 3 | 27 (55%) | 33 (46%) |
| Grade 4 | 9 (18%) | 16 (23%) |
| Visceral GVHD | ||
| Yes | 41 (84%) | 58 (82%) |
| GVHD onset before HSCT Day 100 | ||
| Yes | 34 (69%) | 52 (73%) |
| MB risk groupa | ||
| Low | 8 (17%) | 12 (17%) |
| High | 39 (83%) | 57 (83%) |
| Median MB score (range) | 0.47 (0.10–0.92) | 0.46 (0.10–0.96) |
| Median log10ST2 (range), ng/mL | 5.52 (4.74–6.11) | 5.50 (4.74–6.33) |
| Median time from HSCT to ruxolitinib (range), days | 66 (25–298) | 74 (25–357) |
a
Biomarker data available for 47 patients in the efficacy population and 69 patients in the safety population.
Abbreviations: GVHD, graft‐versus‐host disease; HSCT, hematopoietic stem cell transplantation; MB, MAGIC biomarker 17; ST2, suppressor of tumorigenicity 2.